Skip to main content

Table 2 Main results of the meta-analysis

From: Clinicopathological and prognostic significance of platelet-lymphocyte ratio (PLR) in gastric cancer: an updated meta-analysis

  Factors No. of studies No. of patients Effects model HR (95% CI) p Heterogeneity
I2 Ph
OS Overall 44 26901 Random 1.37 (1.26–1.49) < 0.001 79.90% < 0.001
  Ethnicity
   Caucasian 9 1981 Random 1.31 (0.96–1.79) 0.092 84.10% < 0.001
   Asian 35 24920 Random 1.39 (1.28–1.52) < 0.001 79.20% < 0.001
  Treatment
   Chemotherapy 7 967 Random 1.34 (0.96–1.88) 0.084 76.10% < 0.001
   Surgery 31 24128 Random 1.39 (1.26–1.52) < 0.001 79.10% < 0.001
   Mixed 6 1806 Random 1.38 (0.98–1.93) 0.062 88.20% < 0.001
  Cut-off
   ≤ 150 20 15181 Random 1.36 (1.20–1.54) < 0.001 75.00% < 0.001
   > 150 23 10357 Random 1.42 (1.24–1.63) < 0.001 78.50% < 0.001
  Sample size
   ≤ 500 29 6924 Random 1.42 (1.24–1.64) < 0.001 75.70% < 0.001
   > 500 15 19977 Random 1.34 (1.20–1.50) < 0.001 85.00% < 0.001
DFS Overall 10 5354 Random 1.52 (1.22–1.90) < 0.001 88.60% < 0.001
  1. HR hazard ratio, 95% CI 95% confidence interval, Php values of Q test for heterogeneity test, OS overall survival, DFS disease-free survival